AccScience Publishing / BH / Volume 1 / Issue 2 / DOI: 10.36922/bh.1629
Cite this article
143
Download
1304
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW

Efficacy of pemafibrate in patients with dyslipidemia: A systematic review and meta-analysis of randomized controlled trials

Caroline Cristine Almeida Balieiro1* Maria Esther Barbalho2 Luiza Mendes Fonseca3 Noah Romero Nakajima4 Marcela Mizuhira Gobbo5 Beatriz Polachini Assunes Gonçalves6 Eduardo Cesar Teixeira Sirena7 Alice D. Marinho8 Matheus J. B. Moreira9 Natália Nóbrega de Lima10
Show Less
1 Division of Medicine, Amazonas State University, Manaus, Amazonas, Brazil
2 Division of Medicine, University of Potiguar, Natal, Rio Grande do Norte, Brazil
3 Division of Medicine, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
4 Division of Medicine, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil
5 Division of Medicine, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil
6 Division of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
7 Division of Medicine, University of Fortaleza, Fortaleza, Ceará, Brazil
8 Division of Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
9 Division of Medicine, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
10 Clinics Hospital of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
Brain & Heart 2023, 1(2), 1629 https://doi.org/10.36922/bh.1629
Submitted: 18 August 2023 | Accepted: 8 November 2023 | Published: 21 November 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Abstract

This study aimed to evaluate the efficacy of pemafibrate in patients with hypertriglyceridemia compared to a placebo or fenofibrate through a rigorous systematic review process. To achieve this, we conducted comprehensive searches in the PubMed, Cochrane Library, and Embase databases. The data extraction process was based on published reports, and the assessment of study quality adhered to the PRISMA guidelines. A random-effects model was employed to calculate mean differences (MD) and 95% confidence intervals (CI). Statistical significance was established at P < 0.05, with I² values exceeding 25%, denoting a significant degree of heterogeneity. The primary outcomes of interest were MDs in triglycerides (TG) and non-high-density lipoprotein (HDL) cholesterol. The review protocol was registered with PROSPERO under the identifier CRD42022374852. Nine studies involving 12,644 patients were included, with 6699 (53%) patients receiving pemafibrate. The meta-analysis revealed a significant reduction in serum TG levels in the intervention group (0.4 mg/day) compared to the placebo group (MD: −48.29; 95% CI: −61.45 – −35.13; P < 0.0001; I² = 93%). Pemafibrate (0.4 mg/day) also led to significantly lower non-HDL cholesterol levels compared to control (MD: −6.35; 95% CI: −10.62 – −2.08; P < 0.0001; I² = 82%). There were no significant differences in TG reduction between pemafibrate (0.2 mg/day) and fenofibrate (200 mg/day) (MD: −2.90; 95% CI: −12.90 – 7.11; P = 0.003; I2 = 83%), or between pemafibrate (0.1 mg/day and 0.2 mg/day) and placebo (TG and non-HDL cholesterol levels). In conclusion, pemafibrate demonstrated efficacy in decreasing TG and non-HDL cholesterol levels for dyslipidemia patients, especially at a dosage of 0.4 mg/day compared to a placebo.

Keywords
Dyslipidemia
Pemafibrate
Triglycerides
Meta-analysis
Funding
None.
References
  1. World Health Organization, 2021, WHO Cardiovascular Disease Statistics. Available from: https://www.who.int/ news-room/fact-sheets/detail/cardiovasculardiseases- (cvds) [Last accessed on 2023 May 13].

 

  1. Virani SS, Alonso A, Aparicio HJ, et al., 2021, Heart disease and stroke statistics-2021 Update: A report from the american heart association. Circulation, 143: e254–e743. https://doi.org/10.1161/CIR.0000000000000950

 

  1. Stone NJ, Robinson JG, Lichtenstein AH, et al., 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/ American heart association task force on practice guidelines. J Am Coll Cardiol, 63: 2889–2934. https://doi.org/10.1016/j.jacc.2013.11.002

 

  1. Teramoto T, Sasaki J, Ishibashi S, et al., 2013, Executive summary of the Japan atherosclerosis society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J Atheroscler Thromb, 20: 517–523. https://doi.org/10.5551/jat.15792

 

  1. Baigent C, Blackwell L, Emberson J, et al., 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376: 1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5

 

  1. Carey VJ, Bishop L, Laranjo N, et al., 2010, Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol, 106: 757–763. https://doi.org/10.1016/j.amjcard.2010.05.002

 

  1. Di Angelantonio E, Sarwar N, Perry P, et al., 2009, Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302: 1993–2000. https://doi.org/10.1001/jama.2009.1619

 

  1. Jorgensen AB, Frikke-Schmidt R, West AS, et al., 2013, Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J, 34: 1826–1833. https://doi.org/10.1093/eurheartj/ehs431

 

  1. Nordestgaard BG, Benn M, Schnohr P, et al., 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 298: 299–308. https://doi.org/10.1001/jama.298.3.299

 

  1. Bansal AB, Cassagnol M, 2023, HMG-CoA reductase inhibitors. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK542212/ [Last accessed on 2022 Jul 04].

 

  1. Keech A, Simes RJ, Barter P, et al., 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 366: 1849–1861. https://doi.org/10.1016/S0140-6736(05)67667-2. Erratum in: Lancet, 2006, 368: 1420. Erratum in: Lancet, 2006, 368: 1415.

 

  1. Staels B, Dallongeville J, Auwerx J, et al., 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98: 2088–2093. https://doi.org/10.1161/01.cir.98.19.2088

 

  1. Jun M, Foote C, Lv J, et al., 2010, Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet, 375: 1875–1884. https://doi.org/10.1016/S0140-6736(10)60656-3

 

  1. Davidson MH, Armani A, McKenney JM, et al., 2007, Safety considerations with fibrate therapy. Am J Cardiol, 99: 3C–18C. https://doi.org/10.1016/j.amjcard.2006.11.016

 

  1. Arai H, Yamashita S, Yokote K, et al., 2018, Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb, 25: 521–538. https://doi.org/10.5551/jat.44412

 

  1. Ishibashi S, Arai H, Yokote K, et al., 2018, Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol, 12: 173–184. https://doi.org/10.1016/j.jacl.2017.10.006

 

  1. Fruchart JC, 2017, Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol, 16: 124. https://doi.org/10.1186/s12933-017-0602-y

 

  1. Das Pradhan A, Glynn RJ, Fruchart JC, et al., 2022, Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med, 387: 1923–1934. https://doi.org/10.1056/NEJMoa2210645

 

  1. Page MJ, McKenzie JE, Bossuyt PM, et al., 2021, The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372: n71. https://doi.org/10.1136/bmj.n71

 

  1. Higgins JP, Thomas J, Chandler J, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. Available from: https:// handbook.cochrane.org [Last accessed on 2021 Apr 11].

 

  1. Sterne JA, Savović J, Page MJ, et al., 2019, RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366: l4898. https://doi.org/10.1136/bmj.l4898

 

  1. The Cochrane Collaboration, 2020, Review Manager (RevMan) [Computer Program]. Version 5.4. London: The Cochrane Collaboration. Available from: https://training. cochrane.org/online-learning/core-software-cochrane-reviews/revman [Last accessed on 2021 Aug 23].

 

  1. Arai H, Yamashita S, Yokote K, et al., 2017, Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis, 261: 144–152. https://doi.org/10.1016/j.atherosclerosis.2017.03.032

 

  1. Araki E, Yamashita S, Arai H, et al., 2018, Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care, 41: 538–546. https://doi.org/10.2337/dc17-1589

 

  1. Ginsberg HN, Hounslow NJ, Senko Y, et al., 2022, Efficacy and safety of K-877 (Pemafibrate), a selective PPARα modulator, in European patients on statin therapy. Diabetes Care, 45: 898–908. https://doi.org/10.2337/dc21-1288

 

  1. Ishibashi S, Yamashita S, Arai H, et al., 2016, Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active and placebo-controlled, phase 2 trial. Atherosclerosis, 249: 36–43. https://doi.org/10.1016/j.atherosclerosis.2016.02.029

 

  1. Matsuba I, Matsuba R, Ishibashi S, et al., 2018, Effects of a novel selective peroxisome proliferator-activated receptor-alpha modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig, 9: 1323–1332. https://doi.org/10.1111/jdi.12845

 

  1. Ida S, Kaneko R, Murata K, 2019, Efficacy and safety of pemafibrate administration in patients with dyslipidemia: A systematic review and meta-analysis. Cardiovasc Diabetol, 18: 38. https://doi.org/10.1186/s12933-019-0845-x

 

  1. Mychaleckyj JC, Craven T, Nayak U, et al., 2012, Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care, 35: 1008–1014. https://doi.org/10.2337/dc11-1811

 

  1. Davis TM, Ting R, Best JD, et al., 2011, Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The fenofibrate intervention and event lowering in diabetes (field) study. Diabetologia, 54: 280–290. https://doi.org/10.1007/s00125-010-1951-1
Conflict of interest
All authors report no relationships that could be construed as a conflict of interest.
Share
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing